AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
ABSTRACT
NPM1 mutations occur in approximately 30% of adult acute myeloid leukemia (AML) cases and define a distinct molecular subtype. Nevertheless, NPM1-mutated (NPM1-mut) AML exhibits substantial heterogeneity in co-mutational landscapes, transcriptomic programs, and clinical outcomes (Hernández-Sánchez et al., Leukemia, 2026). Using large-scale surfaceome profiling, we previously identified two NPM1-mut AML subgroups with distinct differentiation states and prognosis (Yu et al., Blood, 2025). However, it is still unknown whether these subgroups differ in response to menin inhibition, and biomarkers for predicting menin inhibitor sensitivity are still lacking. We therefore investigated menin inhibitor vulnerability across NPM1-mut AML subgroups and developed a marker panel for subtype classification and prognostic stratification.
Matched surfaceome and proteome profiles from NPM1-mut AML patients were integrated, and unsupervised clustering using ten algorithms identified two subgroups, C1 and C2. C1 exhibited a primitive state with increased KIT and MEIS1, whereas C2 showed monocytic differentiation, with increased CD14 and HLA class II proteins. Using a menin inhibitor resistance score derived from GSE315341, we predicted that C1 is more sensitive to menin inhibition than C2.
In an independent in-house RNA-seq cohort of 105 NPM1-mut AML patients, C1 and C2 were recapitulated. Importantly, the proportion of C1 cases (47.5%) was comparable to the reported overall response rate (46.9%) to revumenib in NPM1-mut AML (Arellano et al., Blood, 2025). BayesPrism deconvolution using a single-cell reference (Karakaslar et al., Leukemia, 2025) confirmed enrichment of HSC-like populations in C1 and monocyte-like populations in C2. Notably, monocyte-like populations exhibited higher menin inhibitor resistance scores, suggesting an association between monocytic differentiation and reduced sensitivity to menin inhibitor. Co-mutational profiling revealed distinct genomic landscapes between the two subgroups, with FLT3-ITD enriched in C1 (62.5% vs 33.3%, P = 0.028), whereas DNMT3A (33.3% vs 70.2%, P = 0.005) and KRAS mutations (0% vs 15.8%, P = 0.028) were enriched in C2. Consistent with these genomic features, C2 displayed activation of RAS/MEK/ERK signaling, suggesting a potential basis for reduced sensitivity to menin inhibitor. Clinically, C1 was associated with inferior event-free survival (EFS; P = 0.002) and overall survival (OS; P = 0.010). The two-state classification and prognostic relevance were independently recapitulated in two external proteomic cohorts (Jayavelu et al., Cancer Cell, 2022; Pino et al., Cell Reports Medicine, 2024). To experimentally validate these findings, we analyzed 13 primary NPM1-mut AML samples by flow cytometry and ex vivo revumenib treatment. C1 samples showed lower CD11b, HLA-DR, and CD14 expression and retained fewer viable blasts after 7 days revumenib treatment across all tested concentrations, supporting differentiation state as a determinant of menin inhibitor vulnerability.
To facilitate clinical translation, we developed a five-marker panel (PTK7, KIT, CD74, ENTPD1, and CCR2), and generated an individualized risk score for each patient. In the surfaceome discovery cohort, patients with higher risk scores had inferior EFS (P = 0.015) and OS (P = 0.050). Multivariable Cox regression analysis showed that the risk score was independently associated with EFS (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.08-2.64; P = 0.020) and OS (HR, 1.62; 95% CI, 1.01-2.60; P = 0.040). In the in-house RNA-seq cohort, the risk score stratified EFS (P = 0.030) and OS (P = 0.034) and remained independently associated with EFS (HR, 1.22; 95% CI, 1.01-1.46; P = 0.035). Prognostic separation was reproduced in the external Beat AML proteomic cohort (OS, P = 0.001).
Overall, we established a multi-omics framework defining NPM1-mut AML subgroups with distinct biological features, clinical outcomes, and therapeutic vulnerabilities. Our findings demonstrate that differentiation state is a key determinant of menin inhibitor sensitivity, with primitive C1 showing greater sensitivity and monocytic C2 exhibiting relative resistance. The marker panel enables flow cytometry-based subtype classification and prognostic stratification. Collectively, our study provides a strategy for biomarker-guided patient stratification and supports precision selection of patients most likely to benefit from menin inhibitor therapy.